Pressure ulcer healing with Plenusdermax® *Calendula officinalis* L. extract

Cicatrização de úlceras por pressão com extrato Plenusdermax® de *Calendula officinalis* L.

Cicatrización de úlceras por presión con extracto de Plenusdermax® *Calendula officinalis* L.

Marcelo Buzzi¹, Franciele de Freitas², Marcos de Barros Winter³

¹ Rede Sarah de Hospitais de Reabilitação. Brasília, Distrito Federal, Brazil.
² Phytoplenus Bioativos Sociedade Anônima. Pinhais, Paraná, Brazil.
³ Hospital da Santa Casa de Misericórdia de Curitiba, Dermatology Department. Curitiba, Paraná, Brazil.

How to cite this article:


Submission: 01-11-2015    Approval: 09-29-2015

ABSTRACT

Objective: to evaluate the therapeutic benefits of the bioactive extracts of Plenusdermax® *Calendula officinalis* for pressure ulcer healing. Method: an observational cohort study, including 41 patients with a diagnosis of pressure ulcer that was stable in size for more than three months. Patients were evaluated every two weeks, over 30 weeks, for: reduction of the wound area, infection control, types of tissue and exudate, and ulcer microbiology. Results: the proportions of patients who were completely healed after 15 and 30 weeks of treatment were 63% and 88%, respectively, and the mean healing time was 12.5 ± 7.8 weeks. No adverse events were observed during treatment. Conclusion: the results of the study indicate that bioactive *C. officinalis* Plenusdermax® is a safe treatment that promotes healing of pressure ulcers.

Key words: Pressure Ulcer; Wound Healing; Inflammation; Anti-inflammatory; *Calendula Officinalis*.

RESUMO

Objetivo: Avaliar os benefícios terapêuticos do extrato de bioativos de *Calendula officinalis* Plenusdermax® na cicatrização de úlceras de pressão. Métodos: estudo observacional de coorte realizado com quarenta e um pacientes com diagnóstico de úlceras por pressão com tamanho da ferida estável por mais de três meses. Os pacientes foram avaliados quinzenalmente durante 30 semanas, em relação a redução da área da lesão, controle de infecção, tipos de tecido e exsudato, e microbiologia das úlceras. Resultados: a proporção de pacientes que cicatrizaram completamente após 15 e 30 semanas de tratamento foi 63% e 88%, respectivamente, sendo que a média de tempo de cicatrização foi de 12,5 ± 7,8 semanas. Não foram observados eventos adversos durante o tratamento. Conclusão: os resultados do estudo indicam que Plenusdermax® de bioativos de *C. officinalis* é um tratamento seguro que promove a cicatrização de úlceras de pressão.

Descritores: Úlcera por Pressão; Cicatrização; Inflamação; Anti-inflamatória; *Calendula Officinalis*.

RESUMEN

Objetivo: evaluar los beneficios terapéuticos del extracto bioactivo de *Calendula officinalis* Plenusdermax® en la cicatrización de úlceras por presión. Método: estudio observacional de cohorte con cuarenta y un pacientes con diagnóstico de úlceras por presión con un tamaño de herida estable durante más de tres meses. Se evaluó a los pacientes durante 30 semanas cada dos semanas, incluyendo reducción del área de lesión, control de infecciones, tipos de tejidos y secreciones y microbiología de las úlceras. Resultados: la proporción de pacientes con cicatrización completa después de 15 y 30 semanas de tratamiento fue de 63% y 88%, respectivamente, y el promedio de todos los tiempos de cicatrización fue de 12,5 ± 7,8 semanas. No se observaron eventos adversos durante el tratamiento. Conclusión: los resultados del estudio indican que Plenusdermax® con bioactivos de *C. officinalis* es un tratamiento seguro que promueve la cicatrización de úlceras por presión.

Palabras clave: Úlcera por Presión; Cicatrización de Heridas; Inflamación; Anti-inflamatoria; *Calendula Officinalis*.

CORRESPONDING AUTHOR     Marcelo Buzzi   E-mail: marcelo.buzzi@gmail.com
INTRODUCTION

Pressure ulcers, also known as skin ulcers, decubitus ulcers and bedsores, are complex, chronic wounds. They are a frequent cause of morbidity in patients in hospitals and nursing homes, requiring expensive and time-consuming treatments\(^{(9)}\). The healing process of chronic wounds, such as pressure ulcers, is more complex than that of acute wounds, which leads to difficulties in treatment management. Chronic wounds such as pressure ulcers might never heal if not properly treated\(^{(2)}\). Pressure ulcers are areas of localized skin injuries and underlying tissues that usually develop over bony prominences. They occur as a result of continuous pressure on the skin, soft tissue, muscle and bone, leading to localized ischemia, followed by a cascade of processes that result in necrosis\(^{(3)}\). The body areas commonly prone to pressure ulcers include the heels, hips, elbows, back of the head, knees, thighs and toes\(^{(8)}\). Ulcer severity is assessed in several ways, but the pressure ulcer staging system in the United States (United States National Pressure Ulcer Advisory Panel - NPUAP) is the most widely used across the health care community. The NPUAP system includes a four-stage classification, representing progressive severity from intact skin with non-blanchable redness of an area in Stage I, to full thickness tissue loss with exposed bone, tendon or muscle in Stage IV\(^{(2,4)}\).

Local treatment of pressure ulcers is based on the use of dressings that protect the wound and provide a favorable environment for healing to occur. International guidelines for the treatment of pressure ulcers include essential procedures, such as: pressure relief therapy on the injured area, through consistent repositioning of the patient in bed; nutritional diet that is rich in proteins, carbohydrates, vitamins, minerals and important microelements to support formation of granulation tissue; infection control with adequate asepsis and antibiotic therapy; wound bed preparation of injury bed with debridement of necrosis and devitalized tissue; specialized dressings for the preservation of the wound bed; plastic surgery; and, use of topical therapies that are adjuvant to stimulate tissue repair\(^{(4,9)}\).

Several topical products have been developed to reduce the healing time and pain, absorb exudate and blood, and promote rapid healing of the wound\(^{(5-6)}\). The topical adjuvant therapies based on natural products and plants for chronic ulcers have been widely used to reduce healing time, infection, inflammation and edema\(^{(2)}\). *Calendula officinalis* flower extracts are used in many topical preparations, such as anti-inflammatory agents, healing agents of skin and mucous membrane injuries, and for the treatment of herpes, solar erythemas, burns, and dermatitis\(^{(8)}\). The treatment of pressure ulcers in hospitals and home care remains challenging for the nursing team, which motivates research for new, more effective products, despite the various adjuvant therapies currently available, such as antimicrobials, advanced dressings, prepared from natural products, growth factors, among others.

The main objective of this observational clinical cohort study was to evaluate the therapeutic benefits of the bioactive extracts of Plenusdermax\(^{\text{C}}\) *Calendula officinalis* (C. officinalis) in the treatment of pressure ulcers, specifically in the processes of healing, control of microbial colonization, tissue evolution of the wounds, pain management, and also in nursing interventions such as debridement and dressing changes of patients who are bedridden at home or those who are wheelchair users.

METHOD

Ethical aspects

This study was approved by the Institutional Committee of Ethics on Research at PUC-PR and was registered in Plataforma Brasil with the National Commission for Research Ethics. Informed consent was obtained from all patients before screening.

Study design, setting and period

The efficacy of Plenusdermax\(^{\text{C}}\)* C. officinalis hydroglycolic extract in the healing of pressure ulcers was clinically evaluated in a prospective, observational study over a 30-week period. The study was performed between May of 2012 and December of 2013, and the bedridden and wheelchair patients with pressure ulcers were first seen at the outpatient clinic of the Dermatology Department of Hospital da Santa Casa de Misericórdia, Curitiba, Catholic University of Paraná (PUC-PR).

Inclusion and exclusion criteria

Patients with pressure ulcers in the metropolitan area of Curitiba were selected, according to the inclusion and exclusion criteria shown in Box 1.

Study protocol

The nursing team monitored the patients every two weeks for 30 weeks, or until complete healing of the ulcer occurred. Healing was confirmed one week after complete healing and was monitored for another two weeks. At baseline, a complete medical history and an assessment of the current condition of the patients were recorded. Sociodemographic data, medical history, clinical evaluation of wounds, and cleaning procedures were collected and assessed. The initial patient conditions were evaluated in terms of the duration of the ulcer, glycemic control, current activity level, nutritional status, and pain score according to the numerical pain scale\(^{(9)}\). Patients were scored according to the Pressure Ulcer Scale for Healing (PUSH) tool (NPUAP) to estimate the severity and staging of the pressure ulcers\(^{(6)}\). Blood tests results were included: glucose level, serum albumin, blood count and erythrocyte sedimentation rate, bacterioscopy and culture of the ulcer bed.

The microbiological flora was evaluated based on biogram/antibiogram of swab collection from the wound bed. The wounds were photographed and the area determined by computerized planimetry, using Image\(^{\text{J}}\) software (National Institutes of Health, Bethesda, MD, USA), and an area known as standard\(^{(9)}\). The clinical appearance of the wounds was characterized according to the presence of granulation tissue, fibrin, exudate, unpleasant odor, epithelialization and necrosis.
Presentation and topical spray application, was used twice daily (Phytoplenus Bioativos S.A., Pinhais, PR, Brazil), with a liquid along with the informed consent. The spray was thoroughly as well as guidelines for use, care for and change of dressings, and in writing, about the dosage, conditions for drug storage, and in selection.

- Willingness to be visited by the nursing team during the study period.
- Individuals or caregivers who can follow strict protocol recommendations required during the study period.

### Treatment with Plenusdermax®

The healing product based on Phytoplenus Plenusdermax® (Phytoplenus Bioativos S.A., Pinhais, PR, Brazil), with a liquid presentation and topical spray application, was used twice daily after cleaning the wound with sterile saline. The study participants, patients and their caregivers, were informed verbally and in writing, about the dosage, conditions for drug storage, as well as guidelines for use, care for and change of dressings, along with the informed consent. The spray was thoroughly applied to the wound, leaving the wound bed and wound edges moistened with the product. In the case of tunneled ulcers, the product was applied in excess to reach inside the cavity. In the case of Stage II pressure ulcers, the bubbles were not burst and Plenusdermax® was applied twice a day in the wound region, leaving the product to dry for five minutes. In Stage III pressure ulcers, the product was applied twice a day in the wound region and allowed to dry for five minutes. After application and drying of the product, the wound area was occluded with gauze and affixed with sterile micropore. As preventive measures, the incident pressure was reduced and intensive decubitus change was performed (2/2 h to 1/1h). In tunneled ulcers, no gauze was packed into the tunnels, only the orifice was occluded. Exudate control was performed by observing the amount drained, and adjustments were made with more frequent changes of sterile gauze dressings.

In all visits, photographs of the ulcers were obtained by the nursing team for the planimetry, to estimate the wound areas and to evaluate their clinical aspects. Quantitative parameters were evaluated every two weeks from the beginning until the completion of the study (30 weeks). Complete wound closure was defined as complete ulcer epithelialization without any drainage. Patients who experienced an allergic reaction to Plenusdermax®, or a substantial bacterial infection, were treated by the medical director investigator. Patients who suffered allergic reactions were removed from the clinical trial, whereas antibiotic therapy was administered in cases of infection. Patients who had fever and other infectious complications resulting from their wounds during the treatment period were excluded.

### Statistical analysis

Quantitative variables (mean, median, minimum, maximum, and standard deviation) were used for descriptive statistics. The qualitative variables were described as frequencies and percentages. The wound contraction (mm²/week) per week (WoC) was calculated as the initial wound area (iWA) minus the final wound area (fWA), divided by the number of weeks:

$$WoCs = \frac{(iWA - fWA)}{weeks}$$

The healing rate by week (WHR%) was calculated as follows:

$$WHR\%s = \left(\frac{100 \times (iWA - fWA)}{fWA}\right) \text{ weeks}$$

The healing time was evaluated based on the calculation of the cumulative frequency plot. The Mann-Whitney’s U test for matched pairs was used to evaluate the differences in the measured variables at the beginning and at the end of the treatment period. Results with a p < 0.05 were considered statistically significant. Data were analyzed using the Statistical Package for the Social Sciences (SPSS) statistical software, version 20.0 (IBM Corp. Armonk, NY).

### RESULTS

The patient demographics and ulcer characteristics at baseline and after 30 weeks of treatment with Plenusdermax® are
shown in Table 1. Of the 41 patients treated with Plenusdermax®, 14 (34%) were female and 27 (66%) were male. Patients had a mean PUSH score of 9.63 ± 2.41, which rose to 2.24 ± 4.21 at the end of the 30-week treatment. The neuropathic pain scale showed a mild mean pain score (1.6) due to the high number of spinal cord injury patients. The glucose, serum albumin and hemoglobin levels were normal in all patients during the study. There were no significant differences in blood parameters between patients who achieved complete wound closure within 30 weeks and those who did not (p = 0.503, Student’s t-test).

Most patients had Stage III Pressure ulcers (70.7%), typically in the buttocks (43%), sacral (21%) and trochanteric (14%) regions. All pressure ulcers and wounds were characterized as chronic, because the patients developed them on average 41.4 ± 33.6 weeks before the start of the study. The mean wound area at baseline was 3.74 ± 2.34 cm² (range: 1.1 to 11.0 cm²). The biogram/antibiogram swab tests collected from the wound beds and within the lesions showed that 43.9% (18/41) of the ulcers were clinically colonized. Staphylococcus aureus and Escherichia coli were the predominantly present pathogens (15%, 6/41 each), followed by Pseudomonas aeruginosa (7%, 3/41) and Klebsiella pneumoniae (5%, 2/41).

Table 1 – Demographic characteristics of patients with pressure ulcers at the beginning and after 30 weeks of treatment

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>At the beginning</th>
<th>After 30 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parameters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male n (%)</td>
<td>27 (66%)</td>
<td>14 (34%)</td>
</tr>
<tr>
<td>Female n (%)</td>
<td>14 (34%)</td>
<td>27 (66%)</td>
</tr>
<tr>
<td>Age</td>
<td>53 ± 12.3</td>
<td>53 ± 12.3</td>
</tr>
<tr>
<td>Blood tests</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood glucose (mg/dL)</td>
<td>95.3 ± 18.2</td>
<td>8.9 ± 2.34</td>
</tr>
<tr>
<td>Serum albumin (g/dL)</td>
<td>4.04 ± 0.74</td>
<td>4.04 ± 0.74</td>
</tr>
<tr>
<td>Hemoglobin (g/dL)</td>
<td>13.2 ± 1.58</td>
<td>13.2 ± 1.58</td>
</tr>
<tr>
<td>Pain score (1–10)</td>
<td>0.8 ± 1.95&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.8 ± 1.95&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>PUSH Score</td>
<td>2.24 ± 4.21&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.24 ± 4.21&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ulcer parameters:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Classification n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage II</td>
<td>2 (4.9%)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Stage III</td>
<td>3 (7.3%)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Location: n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buttocks</td>
<td>18 (42.8%)</td>
<td>6 (14.3%)&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Sacrum</td>
<td>9 (21.4%)</td>
<td>2 (4.8%)&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Trochanter</td>
<td>6 (14.3%)</td>
<td>1 (2.4%)&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Heel</td>
<td>3 (7.2%)</td>
<td>0 (0.0%)&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Back</td>
<td>2 (4.8%)</td>
<td>0 (0.0%)</td>
</tr>
</tbody>
</table>

Table 1 (concluded)

To be continued

Notes: <sup>a</sup>Significant difference (Mann-Whitney’s U Non-parametric Test, p < 0.05); Values are mean ± standard deviation, unless otherwise stated.

Healing time and reduction of wound area

The time analysis indicated a linear increase in the proportion of patients who achieved complete healing after two to 30 weeks of treatment (Figure 1). Thus, a minimum eight-week period of treatment was necessary for complete ulcer healing, the mean healing time of about 12.5 ± 7.8 weeks. After 15 weeks of treatment, 63% of ulcers were completely healed, with notable improvements in appearance, compared to baseline. After 30 weeks, the proportion of completely healed wounds was 88%. No adverse events were observed during treatment.

Figure 1 – Proportion of healed Pressure ulcers during the 30-week treatment with Plenusdermax®

Based on the fact that Pressure ulcers with larger areas take longer to heal than smaller ulcers, and due to the large variation (range 1.1 to 11.0 cm²) in the initial area of the ulcers, it
was necessary to separate the sample into two groups, based on the initial ulcer area in order to more accurately assess the healing rates. The first group included those with smaller ulcers ranging from 1.0 to 3.9 cm²; the second included those with larger ulcers, ranging from 4.0 to 11.0 cm² (Table 2).

Regarding the duration of ulcers before the study, there was no significant difference between the group of smaller ulcers and the group of larger ulcers (p = 0.850, Mann-Whitney’s U test) (Table 2). As predicted, the group of smaller ulcers had a mean ulcer area at baseline (2.23 cm²) that was significantly lower (p ≤ 0.001) than the group of larger ulcers (7.71 cm²). At the end of 30 weeks, all ulcers smaller than 4.0 cm² were completely healed, whereas 58% of larger ulcers were completely healed (Table 2).

Despite the mean healing time of smaller ulcers being lower than that of larger ulcers during the 30-week period of the study, these values are not statistically different (p = 0.857, Mann-Whitney’s U test). Although not statistically significant (p = 0.465), the wound contraction rate per week (WoC - mm²/week) was 52% higher in the larger ulcers than in the smaller ones, indicating, in absolute terms, a greater contraction ratio in the larger wounds. The percentage healing rate by week (WHR%) that considers the initial wound area in smaller ulcers (14.3%) was significantly two times faster than in the larger ulcers (6.6%). Collectively, these data suggest that the healing benefits of Plenusdermax® is not dependent on the initial size of the pressure ulcer.

**Inflammation and microbiology of the pressure ulcers**

After 30 weeks of treatment with Plenusdermax®, the total number of colonized pressure ulcers was significantly reduced from 18 (44%) to 5 (12.1%) (Mann-Whitney’s U test; p = 0.011; Table 1). It is also important to mention that Plenusdermax® was equally effective against all pathogens identified in the wounds. Therefore, the number of wounds that had an unpleasant odor at baseline (36.6%) was significantly lower after two weeks, and was reduced to 2.4% after treatment. These data are consistent with the dramatic reduction in inflammatory cells and fibrin induced by Plenusdermax®. Equally interesting is the complete disappearance of necrotic tissue after treatment. Taken together, these data demonstrate that Plenusdermax® promotes closure of chronic injury through strong antimicrobial and anti-inflammatory properties that is able to prevent tissue damage.

**DISCUSSION**

In this observational cohort study, the beneficial effects of the bioactive Plenusdermax® C. officinalis spray was tested in healing pressure ulcers in bedridden patients and wheelchair users who used the product regularly at home, with instructions by the nursing team which is a reality in most treatments. The treatment administered to patients followed international guidelines, including repositioning and control of tissue overload, colonization and infection control of ulcers as well as cleaning procedures and care as adjunctive therapy, i.e., Plenusdermax®. However, evidence indicates that in Brazil, the international guidelines for the treatment of pressure ulcers are not regularly followed. An observational study in a general hospital found a low level of adherence to the use of guidelines for the treatment of pressure ulcers, and, in the case of Stage II ulcers, nursing interventions consisted predominantly of cleansing with saline (57%), using vegetable oils (40%) and decubitus change maneuvers, whereas in Stage III ulcers, cleaning interventions with saline (84%) and soapy water (19%), use of debridents such as papain (32 %) and collagenase (14%), and use of antimicrobials, such as silver sulfadiazine (10%) predominated. Another observational cohort study showed that bedridden patients with pressure ulcers treated at home had a high risk of aggravating the healing process, had an overall worse condition which resulted in a

![Table 2](image-url)

**Table 2** - Healing parameters of patients with pressure ulcer treated with Plenusdermax® for 30 weeks

<table>
<thead>
<tr>
<th>Groups according to ulcer size (cm²)</th>
<th>All</th>
<th>Smaller 1.0 – 3.9</th>
<th>Bigger 4.0 – 10.0</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>41</td>
<td>29</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Duration (weeks)</td>
<td>41.4 ± 33.6</td>
<td>42.3 ± 36.2</td>
<td>39.3 ± 22.6</td>
<td>0.850</td>
</tr>
<tr>
<td>Initial area (cm²)</td>
<td>3.74 ± 2.82</td>
<td>2.23 ± 0.81</td>
<td>7.71 ± 2.65</td>
<td>≤ 0.001</td>
</tr>
<tr>
<td>Final area (cm²)</td>
<td>0.55 ± 1.66</td>
<td>0.00 ± 0.00</td>
<td>2.03 ± 2.65</td>
<td>≤ 0.001</td>
</tr>
<tr>
<td>Mean time until healing (weeks)</td>
<td>12.0 ± 7.85</td>
<td>11.7 ± 7.64</td>
<td>12.9 ± 9.45</td>
<td>0.857</td>
</tr>
<tr>
<td>% healing (30 weeks)</td>
<td>87.8</td>
<td>100.0</td>
<td>58.3</td>
<td></td>
</tr>
<tr>
<td>Wound contraction index per week (WoC - mm²/week)</td>
<td>36.1 ± 32.6</td>
<td>30.2 ± 24.3</td>
<td>45.8 ± 41.8</td>
<td>0.465</td>
</tr>
<tr>
<td>Percentage wound rate (WHR%)</td>
<td>12.4 ± 11.1</td>
<td>14.3 ± 11.7</td>
<td>6.6 ± 5.3</td>
<td>0.027</td>
</tr>
</tbody>
</table>

Notes: *Mann Whitney’s Non-parametric U Test, p < 0.05; Values are mean ± standard deviation, unless otherwise stated.
three times higher morbidity when compared to other types of injuries (13). The same study also showed that domiciled patients with increased risk of developing pressure ulcers were those that had limited repositioning capability, did not feel the need to reposition, had fecal incontinence, dementia and/or difficulty feeding themselves (12).

The results obtained with the use of the bioactive extract Plenusdermax® as an adjuvant topical therapy demonstrated that, despite the adversity of home treatment, the ulcer treatment protocol is limited. Eighty-eight percent of patients who had stable ulcers for more than three months achieved complete healing over the 30-week period of the study; the mean healing time was approximately 12 weeks. A percentage of 58% of patients had more difficulty achieving complete healing, probably because they had larger ulcers, some with areas up to 11 cm². Nevertheless, the mean time to healing in these patients was not statistically different from those with smaller ulcers.

The proportion of patients who achieved complete healing with this treatment during the study period corroborated effective treatments for pressure ulcers, since studies showed that high rates of Stage III ulcer healing can reach 59% at 24 weeks, with treatment of up to one year being necessary in some patients (13).

A significant reduction in odor, edema, erythema and bacterial count was observed in the studied patients. This reduction is due to the anti-inflammatory and antibacterial properties of the bioactive extract of Plenusdermax® C. officinalis, since bacteriocidal swabs collected from the wound bed showed significant reduction of colonization by Staphylococcus aureus and Escherichia coli after using Plenusdermax®. Calendula officinalis extracts have proven to have bactericidal and fungicidal effects against pathogenic microorganisms isolated from hospital patients (14). The formation of bacterial biofilms in the wound bed of the lesions is extremely harmful to the tissue and a major contributor to the establishment of a chronic and degrading condition of the ulcers. This situation is further aggravated by the emergence of multidrug-resistant bacteria in response to the abuse of antibiotics, intensifying the search for new strategies to combat bacterial colonization (15). In many pressure ulcer healing therapies, aggressive oxidizing antiseptics are still used very frequently, such as hydrogen peroxide, hypochlorite, acetic acid, chlorhexidine, povidone/iodine, cetrimide, among others, which have antibacterial properties, but are very toxic to healthy granulation tissue (21).

The use of natural extracts for the treatment of chronic skin injuries has always been an alternative adjuvant therapy in the healing area. With the advent of recent and better technologies for obtaining natural bioactives, new therapies have contributed to tissue repair in chronic injuries, preparing the wound bed for better healing (16-18).

Plenusdermax® extract showed an increase in anti-inflammatory, anti-edematous, anti-erythematous and healing activities that corroborate previous clinical and experimental studies using C. officinalis phyto-preparations (19-24). The beneficial effects of Plenusdermax® in healing of pressure ulcers are due to bioactive constituents such as triterpenoids monoeasters, triterpene alcohols, triterpenic oligoglycosides and flavonoids, which may work synergistically to promote wound healing.

The therapy using the bioactive Plenusdermax® C. officinalis spray offered advantages when compared to other adjuvant therapies for the treatment of chronic injuries. The bioactive C. officinalis extract is an aqueous preparation that leaves no solid residue adhering to the wound bed, has ease of application, facilitates the cleaning process and dressing changes, and helps the debridement process. Therefore, it minimizes friction and prevents small traumas on the emerging granulation tissue.

Although the present study is an uncontrolled observational cohort, which has limitations in determining the guaranteed clinical efficacy of randomized controlled clinical trials, the results showed that the use of the bioactive Plenusdermax® C. officinalis spray was a powerful adjuvant in the treatment of pressure ulcers, as it aids nursing interventions such as dressing changes and care of ulcers. Accordingly, the use of the spray helps clean the wound bed, aids in debridement and stimulation of granulation tissue growth, providing a better healing.

**CONCLUSION**

The results of this study indicate that the bioactive extract of Plenusdermax® C. officinalis is a safe and promising therapy for the treatment of pressure ulcers in bedridden and wheelchair users treated at home. The use of Plenusdermax® spray as an adjunctive topical therapy resulted in complete healing of pressure ulcers in 88% of patients during the 30-week period, in addition to helping with wound debridement, dressing change and promotion of significant reduction in bacterial colonization. However, randomized controlled trials on a larger scale with a longer follow-up are required to demonstrate clinical efficacy, to establish optimal treatment guidelines using Plenusdermax®, and also to allow for these results to be validated in a broad population.

**REFERENCES**


